PARKMAN HEALTHCARE PARTNERS LLC other names

{{ Info.Overview }}
Revenue: {{ Info.Revenue | formatUSD }} Headquarters: {{ Info.Headquarters }}
{{ Info.Homepage }}

Adviser Profile

As of Date:

03/28/2024

Adviser Type:

- Large advisory firm

Number of Employees:

9 12.50%

of those in investment advisory functions:

5

Registration:

SEC, Approved, 3/15/2019

AUM:

942,517,802 59.25%

of that, discretionary:

942,517,802 59.25%

Private Fund GAV:

362,298,326 38.04%

Avg Account Size:

157,086,300 32.71%

SMA’s:

NO

Private Funds:

2

Contact Info

(20 xxxxxxx

Websites :
Client Types:

+

Advisory Activities:

+

Compensation Arrangments:

+

Reported AUM

Discretionary
Non-discretionary
592M 507M 423M 338M 254M 169M 85M
2019 2020 2021 2022 2023

Recent News

Parkman Healthcare Partners LLC Buys AbbVie Inc, Fulcrum Therapeutics Inc, Seagen Inc, Sells ...
11/13/2021

Related Stocks: FULC, SGEN, IMUX, AVTR, COO, PFMT, ABBV, AMGN, BRKS, RCM, SMLR, ATEC, ISRG, ITMR, XLRN, NVRO, PTGX, INFU,

gurufocus.com

Stereotaxis Inc.
03/31/2021

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Barrons

icad Inc.
03/30/2021

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Barrons


Private Funds Structure

Fund Type Count GAV
Hedge Fund 1 $356,305,948
Private Equity Fund 1 $5,992,378

Similar advisers

Adviser Hedge Fund Liquidity Fund Private Equity Fund Real Estate Fund Securitized Asset Fund Venture Capital Fund Other Fund Total Private Fund GAV AUM # funds
VALENCE8 798.4m - 73.7m - - - - 872.1m 909.5m 4
SYCALE ADVISORS 1.3b - 42.2m - - - - 1.3b 572.1m 8
WHITEFORT CAPITAL MANAGEMENT, LP 677.6m - 7.6m - - - - 685.2m 685.2m 2
ALLIANCE ADVISORY & SECURITIES, LLC 5.5m - 5.6m - - - - 11.2m 608.4m 2
SUPERSTRING CAPITAL MANAGEMENT LP 258.5m - 48.9m - - - - 307.4m 371.1m 2
FERNWOOD INVESTMENT MANAGEMENT, LLC 20.5m - 6.0m - - - - 26.5m 435.7m 2
LAGO ASSET MANAGEMENT 229.2m - 61.9m - - - - 291.2m 380.6m 12
FORAGER CAPITAL MANAGEMENT, LLC 328.2m - 22.1m - - - - 350.3m 350.3m 2
X-SQUARE CAPITAL 57.2m - 106.4m - - - - 163.6m 423.6m 2
SEGRA CAPITAL MANAGEMENT, LLC 427.0m - 23.0m - - - - 449.9m 449.9m 2

Private Funds



Employees




Top Holdings

Stock Ticker Stock Name $ Position % Position $ Change # Change
101137107 BOSTON SCIENTIFIC CORP $42,478,100 6.00% 46.00% 30.00%
45784P101 INSULET CORP $36,183,749 5.00% 132.00% 97.00%
91307C102 UNITED THERAPEUTICS CORP DEL $35,480,418 5.00% 20.00% -13.00%
216648501 COOPER COS INC $26,923,145 4.00% -7.00% 8.00%
532457108 ELI LILLY & CO $28,658,899 4.00% 15.00% -1.00%
00847X104 AGIOS PHARMACEUTICALS INC $19,249,458 3.00%
54300N103 LONGBOARD PHARMACEUTICALS IN $18,763,631 3.00% 25.00% 0.00%
88033G407 TENET HEALTHCARE CORP $19,811,759 3.00% -34.00% -48.00%
87164F105 SYNDAX PHARMACEUTICALS INC $12,332,330 2.00% -34.00% -23.00%
78349D107 RXSIGHT INC $17,854,786 2.00% -16.00% -28.00%

Brochure Summary

Overview

A. Parkman Healthcare Partners LLC (the “Adviser” or “Parkman”) was formed in November 2018 as a Delaware limited liability company and has its principal place of business in Stamford, Connecticut. The principal owner of Parkman is Greg Martinez (the “Principal”), who has the overall responsibility for the day-to-day supervision and management of Parkman’s business. Parkman acts as the investment manager for: (i) a sponsored master-feeder structure (the “Fund”), a sponsored special purpose vehicle (the “SPV”); and (iii) sub-advised accounts (each a “Managed Account”, which, collectively with the Fund and SPV, are referred to as the “Clients”)).1 The Fund and SPV are for sophisticated, qualified investors (“Investors”). B. Parkman pursues its investment strategy through managing its Clients. Parkman has discretion with respect to investment decisions made for the Clients. The Adviser provides its services to the Clients as described in the Client’s confidential offering memorandum and governing documents or applicable investment management agreement. Parkman’s investment strategy aims to protect and grow capital by taking long and short positions in a portfolio that consists primarily of a broad range of global equities, focusing on the healthcare sector. Parkman uses a fundamental bottom-up analysis to identify what it considers to be undervalued investments and to capture fundamental valuation
disparities. C. While each of its Clients follow the general strategy mentioned above, the Adviser may tailor the specific advisory services with respect to the individual needs of such Clients pursuant to the agreed upon terms described in the applicable governing documents, including but not limited to an investment management agreement (referred to collectively as “Offering Documents”). Each advisory agreement was separately negotiated and designed to suit the needs of the respective Client and its respective investment guidelines. Such advisory agreements may impose restrictions on Parkman’s ability to invest in certain securities or types of securities. Additional portfolio restrictions may also include exposure limits, concentration limits, industry and sector limits, geographical limits and liquidity limits. D. The Adviser will not participate in wrap fee programs. E. As of December 31, 2023, the Adviser managed $942,517,802 in regulatory assets under management on a discretionary basis. Parkman does not manage any advisory client assets on a non-discretionary basis. 1 As a registered investment adviser, the Adviser owes a fiduciary duty to all of its clients. In 2006, the decision by the Court of Appeals for the D.C. Circuit in Goldstein v. SEC, 451 F.3d 873 (D.C. Cir. June 23, 2006), with respect to private funds, clarified that the “client” of an investment adviser to a private fund is the fund itself and not an investor in the fund.